CTLA4 and ovarian cancer: In recent years, immunotherapies such as immune checkpoint inhibitors have developed rapidly and have been investigated for the maintenance treatment of ovarian cancer, including anti-PD-1/PD-L1 and anti-CTLA-4 (Odunsi, 2017; Yang et al., 2020).